Marina Moskalenko
Overview
Explore the profile of Marina Moskalenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
758
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brooks T, Gao D, Dorris K, Boone K, Mirsky D, Staulcup S, et al.
J Neurosurg Pediatr
. 2024 Sep;
34(6):642-648.
PMID: 39332032
Objective: In a cohort of patients who were treated with resection and adjuvant radiotherapy (RT) for adamantinomatous craniopharyngioma (ACP), the authors aimed to determine whether gross tumor volume (GTV) at...
2.
Shiao J, Gao D, Mueller A, Holt D, Moskalenko M, Zaccone J, et al.
Adv Radiat Oncol
. 2024 Feb;
9(2):101372.
PMID: 38405320
Purpose: Limited structured educational programs are available for the continued professional development of radiation oncology nurses. In this study, we evaluated a pilot curriculum focusing on clinical workflow and toxicity...
3.
Moskalenko M, Jones B, Mueller A, Lewis S, Shiao J, Zakem S, et al.
Curr Oncol
. 2023 May;
30(5):5054-5061.
PMID: 37232840
Fiducial markers are utilized for image guided radiotherapy (IGRT) alignment during the delivery of liver stereotactic body radiosurgery (SBRT). There are limited data demonstrating the impact of matching fiducials on...
4.
Moyer A, Vogel J, Lai S, Kim H, Chin R, Moskalenko M, et al.
J Gastrointest Surg
. 2023 Feb;
27(5):980-989.
PMID: 36759387
Background: Total neoadjuvant therapy for locally advanced rectal cancer may include induction chemotherapy and chemoradiation or short-course radiotherapy and consolidative chemotherapy. Methods: Patients with clinical stage 2 or 3 rectal...
5.
Moskalenko M, Robin T
Transl Cancer Res
. 2022 Feb;
10(5):2527-2536.
PMID: 35116569
Radiation therapy plays a key role in the management of intracranial metastatic disease. Historically, systemic therapy was able to address extracranial disease but not cross the blood-brain barrier and radiation...
6.
Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy
Chapman B, Lai S, Friedrich T, Lieu C, Moskalenko M, Olsen J, et al.
Dis Colon Rectum
. 2022 Jan;
66(4):521-530.
PMID: 34984995
Background: Total neoadjuvant therapy in rectal cancer may increase pathological complete response rates, potentially allowing for a nonoperative approach. Objective: The objective of this study was to identify patient and...
7.
Moskalenko M, Zaccone J, Fiscelli C, Wieworka J, Anderson R, Choflet A, et al.
Int J Radiat Oncol Biol Phys
. 2021 Feb;
110(3):667-671.
PMID: 33524544
Purpose: Nurses in the radiation oncology (RO) clinic have a critical role in the management of patients receiving radiation therapy. However, limited data exist regarding the exposure of nurses to...
8.
Cubas R, Khan Z, Gong Q, Moskalenko M, Xiong H, Ou Q, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33127657
Background: Cancer immunotherapy has evolved from interferon-alpha (IFNα) and interleukin-2 in the 1980s to CTLA-4 and PD-1/PD-L1 checkpoint inhibitors (CPIs), the latter highlighting the importance of enhancing T-cell functions. While...
9.
Xiong H, Mittman S, Rodriguez R, Pacheco-Sanchez P, Moskalenko M, Yang Y, et al.
Cancer Immunol Res
. 2019 May;
7(6):963-976.
PMID: 31064777
Exhausted T cells have been described in cancer patients and murine tumor models largely based on their expression of various inhibitory receptors. Understanding of the functional attributes of these cells...
10.
Xiong H, Mittman S, Rodriguez R, Moskalenko M, Pacheco-Sanchez P, Yang Y, et al.
Cancer Res
. 2019 Jan;
79(7):1493-1506.
PMID: 30679180
Checkpoint inhibitors like anti-PD1/PD-L1 have demonstrated significant therapeutic efficacy in a subset of patients partly through reinvigoration of CD8 T cells. However, their impact on myeloid cells remains largely unknown....